Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate...

|By:, SA News Editor

Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing.